Colchicine Versus Beta-blockers, Angiotensin-converting Enzyme Inhibitors, and Statins for Prevention of Chemotherapy-Induced Cardiomyopathy
BASiC-CIC Trial is a multicenter, double-blinded, randomized, placebo-controlled clinical trial to investigate whether repurposing colchicine or a combination of beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and statins will be effective as a prophylactic treatment for the prevention of chemotherapy-induced cardiomyopathy, reduction of major adverse cardiovascular events, and all-cause mortality.
- EligibilityCriteria: Inclusion Criteria:  Willing and able to provide written informed consent prior to performing study procedures. A cancer patient who is a candidate for a guideline-directed, anthracycline-based chemotherapy with or without the anti-HER2 trastuzumab. Baseline LVEF ≥ 50% without evident structural heart disease by pre-treatment echocardiographic examination.  Exclusion Criteria:  Critically ill Cancer patients who are admitted to ICU. Ischemic cardiomyopathy with LVEF ≤ 50%. Dilated cardiomyopathy with LVEF ≤ 50%. Advanced valvular heart disease (severe valvular affection in the form of stenosis or regurgitation). Systolic BP < 90 mmHg or diastolic BP < 60 mmHg. Liver cell failure. End-stage chronic kidney disease on regular dialysis. Pregnancy. Lactation. Chronic muscle diseases such as dermatomyositis, polymyositis, or muscular dystrophy. Acute trauma or burns within 2 weeks. History of allergy to the implemented drugs. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult